Deadly Outbreak Puts Compounded Drugs In FDA's Crosshairs

Law360, New York (October 4, 2012, 9:46 PM EDT) -- A deadly meningitis outbreak connected to steroids made by a Massachusetts compound pharmacy could drive the U.S. Food and Drug Administration to crack down on compounded medications, a product it has traditionally left to states to regulate, attorneys say.

At least 35 people in six states have contracted fungal meningitis, and at least five have died, after receiving injections of a steroid manufactured by the New England Compounding Center, federal officials said Thursday afternoon. The steroid, methylprednisolone acetate, is typically used by physicians to treat back...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.